Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).
Age ≥ 18 at time of consent
Ability to provide written informed consent and HIPAA authorization
Stage III NSCLC per AJCC 8th edition guideline, confirmed by pathological diagnosis and PET/CT.
To receive standard definitive concurrent chemoradiation therapy per NCCN guidelines.
Patients treated with stereotactic body radiotherapy (SBRT).
Prior thoracic radiotherapy.
History of a severe anaphylactic reaction to iodinated contrast.
Renal insufficiency (defined as estimated CrCl less than 30 mL/min).
Single group
PET/CT 18F-Flurpiridaz Rest/Stress Test
Diagnostic testA two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET/CT before and 3 months after SOC radiation treatment.
Coronary CT Angiography (CCTA)
DeviceCoronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.
18F-Flurpiridaz
DrugA two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET/CT before and 3 months after SOC radiation treatment
Change of MBF (myocardial blood flow)
Assessed using a two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET/CT
Changes in myocardial blood flow to the cardiac base
Assessed using a two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET/CT
Changes in myocardial blood flow to the left ventricle
Assessed using a two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET/CT
Changes in myocardial blood flow to right coronary artery
Assessed using a two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET/CT
Changes in myocardial blood flow to left circumflex artery
Assessed using a two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET/CT
Click on the lead sponsor to view all of their trials.
